Correlation between expression of ovarian tumor domain-containing ubiquitin aldehyde binding protein 1 and programmed cell death-ligand 1 in non-small cell lung cancer

CHEN Xiuhong; LI Kun; JIN Shuang; ZHANG Zhongmian

doi:10.7619/jcmp.20213152

Journal of Clinical Medicine in Practice > 2021 > 25(23): 31-36. > DOI: 10.7619/jcmp.20213152

CHEN Xiuhong, LI Kun, JIN Shuang, ZHANG Zhongmian. Correlation between expression of ovarian tumor domain-containing ubiquitin aldehyde binding protein 1 and programmed cell death-ligand 1 in non-small cell lung cancer[J]. Journal of Clinical Medicine in Practice, 2021, 25(23): 31-36. DOI: 10.7619/jcmp.20213152

Citation:

PDF (1737 KB)

Correlation between expression of ovarian tumor domain-containing ubiquitin aldehyde binding protein 1 and programmed cell death-ligand 1 in non-small cell lung cancer

Department of Oncology, the Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450014

More Information

Received Date: August 04, 2021
Available Online: December 20, 2021

Graphical Abstract

Abstract

Abstract

Objective
To explore the correlation between ovarian tumor domain-containing ubiquitin aldehyde binding protein 1 (OTUB1) and programmed cell death-ligand 1 (PD-L1) in non-small cell lung cancer (NSCLC).
Methods
Differences of OTUB1 mRNA between NSCLC and corresponding non-tumor normal tissues in the Cancer Genome Atlas (TCGA) were analyzed. The correlation on mRNA expression between OTUB1 and PD-L1 in NSCLC in Gene Expression Profiling Interactive Analysis (GEPIA) was discussed. The protein expressions of OTUB1 and PD-L1 in 46 cases of NSCLC and 41 cases of corresponding non-tumor normal tissues were detected by immunohistochemistry, and the clinical case data and follow-up data were collected. The expression difference of OTUB1 between cancer tissues and adjacent tissues, the correlations between OTUB1 and PD-L1 as well as clinicopathological features, and the predictive significance for recurrence free survival (RFS) were analyzed.
Results
There were significant differences in mRNA and protein expressions of OTUB1 between NSCLC and corresponding non-tumor normal tissues (P < 0.05). There was no correlation in mRNA expression between OTUB1 and PD-L1 in NSCLC tissues (P>0.05), but there was a correlation in protein expression between OTUB1 and PD-L1 (P=0.029). OTUB1 was correlated with TNM staging (P=0.039), but had no correlation with age, history of smoking, degree of differentiation, number of metastatic lymph nodes and pathological type (P>0.05). Kaplan-Meier analysis showed that TNM staging (P < 0.001), the number of metastatic lymph nodes (P=0.001) and the degree of differentiation (P=0.042)were the influencing factors of RFS. The median RFS of negative and positive OTUB1 were 18 months and 19 months, respectively, and there was no significant difference (P>0.05). COX multivariate analysis showed that the degree of differentiation (P=0.005) and TNM staging (P=0.006) were the independent risk factors for RFS.
Conclusion
The mRNA and protein expression levels of OTUB1 in NSCLC tissue are higher than those in corresponding non-tumor normal tissues. In terms of protein level, OTUB1 is positively correlated with PD-L1. OTUB1 expression is related to TNM staging.

FullText(HTML)

References (27)

References

[1]	BARTA J A, POWELL C A, WISNIVESKY J P. Global epidemiology of lung cancer[J]. Ann Glob Heal, 2019, 85(1): 8. doi: 10.5334/aogh.2419
[2]	OSMANI L, ASKIN F, GABRIELSON E, et al. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy[J]. Semin Cancer Biol, 2018, 52(pt 1): 103-109. http://www.ncbi.nlm.nih.gov/pubmed/29183778
[3]	ZOU W, WOLCHOK J D, CHEN L. PD-L1(B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations[J]. Sci Transl Med, 2016, 8(328): 328rv4. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859220/pdf/nihms-780239.pdf
[4]	EIKAWA S, NISHIDA M, MIZUKAMI S, et al. Immune-mediated antitumor effect by type 2 diabetes drug, metformin[J]. PNAS, 2015, 112(6): 1809-1814. doi: 10.1073/pnas.1417636112
[5]	YANG Y, HSU J M, SUN L, et al. Palmitoylation stabilizes PD-L1 to promote breast tumor growth[J]. Cell Res, 2019, 29(1): 83-86. doi: 10.1038/s41422-018-0124-5
[6]	ZHANG J, BU X, WANG H, et al. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance[J]. Nature, 2018, 553(7686): 91-95. doi: 10.1038/nature25015
[7]	LIM S O, LI C W, XIA W, et al. Deubiquitination and stabilization of PD-L1 by CSN5[J]. Cancer Cell, 2016, 30(6): 925-939. doi: 10.1016/j.ccell.2016.10.010
[8]	DENG S, ZHOU X, XU J. Checkpoints under traffic control: from and to organelles[J]. Adv Exp Med Biol, 2020, 1248: 431-453. doi: 10.1007/978-981-15-3266-5_18
[9]	FRAME S, COHEN P. GSK3 takes centre stage more than 20 years after its discovery[J]. Biochem J, 2001, 359(pt 1): 1-16. http://www.biochemj.org/content/359/1/1.full-text.pdf
[10]	YANG Y, HSU J M, SUN L, et al. Palmitoylation stabilizes PD-L1 to promote breast tumor growth[J]. Cell Res, 2019, 29(1): 83-86. doi: 10.1038/s41422-018-0124-5
[11]	ZHU Q, FU Y, LI L, et al. The functions and regulation of Otubains in protein homeostasis and diseases[J]. Ageing Res Rev, 2021, 67: 101303. doi: 10.1016/j.arr.2021.101303
[12]	ZHU D, XU R, HUANG X, et al. Deubiquitinating enzyme OTUB1 promotes cancer cell immunosuppression via preventing ER-associated degradation of immune checkpoint protein PD-L1[J]. Cell Death Differ, 2021, 28(6): 1773-1789. doi: 10.1038/s41418-020-00700-z
[13]	TOMCZAK K, CZERWI? SKA P, WIZNEROWICZ M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge[J]. Contemp Oncol: Pozn, 2015, 19(1a): A68-A77. http://www.scienceopen.com/document_file/ac4bb8d0-842c-4c65-924e-c0b532b5ab9c/PubMedCentral/ac4bb8d0-842c-4c65-924e-c0b532b5ab9c.pdf
[14]	TANG Z, LI C, KANG B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses[J]. Nucleic Acids Res, 2017, 45(w1): W98-W102. doi: 10.1093/nar/gkx247
[15]	ZHOU Y, WU J, FU X, et al. OTUB1 promotes metastasis and serves as a marker of poor prognosis in colorectal cancer[J]. Mol Cancer, 2014, 13: 258. doi: 10.1186/1476-4598-13-258
[16]	WENG W, ZHANG Q, XU M, et al. OTUB1 promotes tumor invasion and predicts a poor prognosis in gastric adenocarcinoma[J]. Am J Transl Res, 2016, 8(5): 2234-2244. http://ajtr.org/files/ajtr0023747.pdf
[17]	KARUNARATHNA U, KONGSEMA M, ZONA S, et al. OTUB1 inhibits the ubiquitination and degradation of FOXM1 in breast cancer and epirubicin resistance[J]. Oncogene, 2016, 35(11): 1433-1444. doi: 10.1038/onc.2015.208
[18]	IGLESIAS-GATO D, CHUAN Y C, JIANG N, et al. Erratum: OTUB1 de-ubiquitinating enzyme promotes prostate cancer cell invasion in vitro and tumorigenesis in vivo[J]. Mol Cancer, 2015, 14: 88. doi: 10.1186/s12943-015-0341-1
[19]	WANG Y, WANG H, YAO H, et al. Regulation of PD-L1: emerging routes for targeting tumor immune evasion[J]. Front Pharmacol, 2018, 9: 536. doi: 10.3389/fphar.2018.00536
[20]	ALTUN M, WALTER T S, KRAMER H B, et al. The human otubain2-ubiquitin structure provides insights into the cleavage specificity of poly-ubiquitin-linkages[J]. PLoS One, 2015, 10(1): e0115344. doi: 10.1371/journal.pone.0115344
[21]	WIENER R, ZHANG X, WANG T, et al. The mechanism of OTUB1-mediated inhibition of ubiquitination[J]. Nature, 2012, 483(7391): 618-622. doi: 10.1038/nature10911
[22]	FEDCHENKO N, REIFENRATH J. Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue-a review[J]. Diagn Pathol, 2014, 9: 221. doi: 10.1186/s13000-014-0221-9
[23]	THOMPSON R H, KUNTZ S M, LEIBOVICH B C, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up[J]. Cancer Res, 2006, 66(7): 3381-3385. doi: 10.1158/0008-5472.CAN-05-4303
[24]	HSU M C, HSIAO J R, CHANG K C, et al. Increase of programmed death-1-expressing intratumoral CD8 T cells predicts a poor prognosis for nasopharyngeal carcinoma[J]. Mod Pathol, 2010, 23(10): 1393-1403. doi: 10.1038/modpathol.2010.130
[25]	HAMANISHI J, MANDAI M, IWASAKI M, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer[J]. PNAS, 2007, 104(9): 3360-3365. doi: 10.1073/pnas.0611533104
[26]	BAIETTI M F, SIMICEK M, ABBASI ASBAGH L, et al. OTUB1 triggers lung cancer development by inhibiting RAS monoubiquitination[J]. EMBO Mol Med, 2016, 8(3): 288-303. doi: 10.15252/emmm.201505972
[27]	LI Y, SUN X X, ELFERICH J, et al. Monoubiquitination is critical for ovarian tumor domain-containing ubiquitin aldehyde binding protein 1(Otub1) to suppress UbcH5 enzyme and stabilize p53 protein[J]. J Biol Chem, 2014, 289(8): 5097-5108. doi: 10.1074/jbc.M113.533109

[1]	LI Bo, ZHANG Jie. Effects of doxorubicin combined with cisplatin on efficacy, survival rate and toxicity in cervical cancer patients with radiotherapy[J]. Journal of Clinical Medicine in Practice, 2020, 24(11): 108-110. DOI: 10.7619/jcmp.202011029
[2]	ZHAO Lianghui, XU Zhongju, WU Wei. Effect of comprehensive nursing for nasopharyngeal carcinoma patients with oral mucosal reaction caused by radiotherapy[J]. Journal of Clinical Medicine in Practice, 2017, (14): 133-135. DOI: 10.7619/jcmp.201714040
[3]	WANG Ying, YUAN Xin, YAN Mingquan. The clinical observation of enternal nutrition on the radiotherapy of nasopharyngeal carcinoma patients after percutaneous endoscopic gastrostomy[J]. Journal of Clinical Medicine in Practice, 2014, (9): 93-95. DOI: 10.7619/jcmp.201409027
[4]	MA Li, MA Xiaoxia, LV Shuling. The influence of individualized nursing intervention on cancer-related fatigue in nasopharyngeal carcinoma patients with radiotherapy[J]. Journal of Clinical Medicine in Practice, 2014, (8): 10-13. DOI: 10.7619/jcmp.201408004
[5]	LIU Xiaojing, CHEN Suping, ZHANG Xizhi, HUA Wei. Application of PET/CT image fusion for conformal radiotherapy in nasopharyngeal carcinoma[J]. Journal of Clinical Medicine in Practice, 2013, (19): 41-43. DOI: 10.7619/jcmp.201319014
[6]	CHEN Ling. Application of cognitive behavioral nursing in treatment of nasopharyngeal carcinoma patients with radiotherapy[J]. Journal of Clinical Medicine in Practice, 2013, (18): 10-12. DOI: 10.7619/jcmp.201318004
[7]	WU Xinghong. Effect of evidence-based nursing on treatment of nasopharyngeal carcinoma patients with radiotherapy[J]. Journal of Clinical Medicine in Practice, 2013, (18): 7-9. DOI: 10.7619/jcmp.201318003
[8]	CHEN Yan, LV Shuling, ZHAO Xiaoli. Early prevention and nursing intervention for radioactive oral mucosal reactions in patients with nasopharyngeal carcinoma[J]. Journal of Clinical Medicine in Practice, 2013, (8): 18-20. DOI: 10.7619/jcmp.201308007
[9]	ZHAI Zhenghuan, ZHOU Xiang, JI Pingping. Nursing countermeasures for mitigating post-radiotherapy adverse reactions in patients with nasopharyngeal carcinoma[J]. Journal of Clinical Medicine in Practice, 2013, (8): 15-17. DOI: 10.7619/jcmp.201308006
[10]	YANG Xuan. Observation on the effects of compound matrine injection on the toxic and side effects in chemotherapy of breast cancer[J]. Journal of Clinical Medicine in Practice, 2013, (5): 105-107. DOI: 10.7619/jcmp.201305034

Cited By

Cited by

Periodical cited type(5)

1.	赵蕾，魏岚，费晓璐. 血糖间隙对药物保守治疗脑卒中患者症状性颅内出血的预测价值. 国际老年医学杂志. 2024(04): 414-418 .
2.	廖青玲. 血清CK-MB、MYO、cTnI、NT-proBNP联合检测在急性心肌梗死早期诊断中应用价值. 黑龙江医学. 2024(15): 1844-1846 .
3.	韩佳玉，徐明星. 基于循证理念的延续护理对老年心血管疾病患者介入术后再发主要心血管不良事件的影响. 中国医药导报. 2023(10): 170-173+193 .
4.	刘亚楠，张逸，吴慧. 司美格鲁肽对2型糖尿病患者心血管危险因素的影响. 糖尿病新世界. 2023(10): 73-76 .
5.	张俊峰，苏绍红. 急性心肌梗死主要不良心血管事件的血清指标预测研究. 实用临床医药杂志. 2023(23): 31-36+42 . 本站查看

Other cited types(0)

Get Citation

PDF

XML

Article views (296) PDF downloads (14) Cited by(5)

Turn off MathJax

Article Contents

Abstract

References

Correlation between expression of ovarian tumor domain-containing ubiquitin aldehyde binding protein 1 and programmed cell death-ligand 1 in non-small cell lung cancer